Encrypted login | home

Program Information

New Designed Radiotherapy Biomaterials with Reservoir and Coated Spacers for Radiotherapy Applications

no image available
F Boateng

F Boateng1*, M Moreau1,W Ngwa1,2 , (1) ,University of Massachusetts Lowell, (2) Harvard Medical School, Boston, MA

Presentations

WE-AB-605-10 (Wednesday, August 2, 2017) 7:30 AM - 9:30 AM Room: 605


Purpose: To investigate the feasibility of employing newly designed radiotherapy biomaterials with reservoir (hollow spacers, applicators) loaded nanoparticles/drug in comparison to coated spacers, and to determine the dosimetric impact on dose enhancement ratio in radiotherapy applications.

Methods: The approach was to develop models to compare the experimentally reported coated spacer to a reservoir/hollow spacer (HS) loaded with nanoparticles (NP) to study the dosimetric impact of different eluting spacers and radioisotopes. The mathematical models developed were based on experimental data and in vitro determined diffusion coefficient of 5.54E-10 cm^2/s.

Results: The results showed significant reduction of preload release time from HS. Our proposed model agreed with in vitro experimental results of 99.9% release rate of GdNP (gadolinium NP) in 41 days, in comparison to coated spacers (over 3 months) reported by Nagesha et al, 2010; which highlighted therapeutic advantage of HS over other coated spacers for radiotherapy applications. On average, our model predicted 86% release rate based on diffusion coefficient (5.54E-10 cm^2/s). Based on modified model HS could be tailored to release 99.9% of preload in a short period: 10, 15, 17, 35 days in comparison to model for normal HS confirmed experimentally.

Conclusion: The results highlight the dosimetric advantages of the new designed eluting reservoir/hollow biomaterials (HBs) over eluting coated spacers. HBs could be tailored in different shapes to release the preload at a desired period (short or long) for specific applications. Our findings suggest that the HBs also could be employed with I-125 and other short-lived radioisotopes like Pd-103 and Cs-131depending on the HB design used. Our proposed models could provide theoretical and scientific platform for research development of next generation of radiotherapy biomaterials loaded with appropriate known amount of NP/drug for radiotherapy applications (including, brachytherapy, MRI, CT, chemoradiotherpy), and other drug delivery disciplines, reducing experimental time and cost.


Contact Email: